← Back to Search

HLADQA1*05A>G screening for Inflammatory Bowel Disease (INHERIT Trial)

N/A
Waitlist Available
Led By Aze A Wilson, MD, PhD
Research Sponsored by Western University, Canada
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

INHERIT Trial Summary

This trial looks at whether a gene test can help predict who will form antibodies to a certain drug, which would then help guide clinicians in deciding whether to put patients on combination therapy.

Eligible Conditions
  • Inflammatory Bowel Disease
  • Crohn's Disease
  • Ulcerative Colitis

INHERIT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
incidence of infliximab anti-drug antibodies
Secondary outcome measures
incidence of combination therapy (infliximab and one of methotrexate or azathioprine) -related adverse drug events
Adverse reaction to drug
incidence of infliximab discontinuation
+5 more

INHERIT Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: preemptive screeningExperimental Treatment1 Intervention
prospective HLADQA1*05A>G screening and targeted administration of combination therapy of infliximab with one of either methotrexate or azathioprine.
Group II: standard of careActive Control1 Intervention
administration of combination therapy with infliximab and one of methotrexate or azathioprine is at the discretion of the treating physician. HLADQA1*05A>G genotyping will be performed retrospectively.

Find a Location

Who is running the clinical trial?

Western University, CanadaLead Sponsor
239 Previous Clinical Trials
57,321 Total Patients Enrolled
Aze A Wilson, MD, PhDPrincipal InvestigatorWestern University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What criteria must be met to qualify for enrollment in this medical experiment?

"This medical study requires 162 participants, ranging from 18 to 85 years of age and who have ileocolitis. Additional entry criteria include those with prior experience using non-TNF based therapies."

Answered by AI

Are there any openings remaining for prospective study participants?

"Based on records found on clinicaltrials.gov, this study is no longer enrolling participants; the initial advertisement was posted September 1st 2020 and last edited a year ago in late September 2019. Nonetheless, there are still 535 other medical trials actively recruiting patients at present."

Answered by AI

Is this clinical investigation open to individuals over the age of 45?

"This study is recruiting individuals aged 18 and over, up to the age of 85."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Preemptive HLA Genotyping for the Safe Use of Infliximab-combination Therapy in Inflammatory Bowel Disease
2020. "Preemptive HLA Genotyping for the Safe Use of Infliximab-combination Therapy in Inflammatory Bowel Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04109300.
All > Inflammatory Bowel Disease
~35 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top